Fexofenadine: Difference between revisions
Appearance
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #219 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:H1 receptor antagonists]] | |||
[[Category:Antihistamines]] | |||
Latest revision as of 10:43, 23 May 2026
Fexofenadine
Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Seasonal allergic rhinitis0, Chronic idiopathic urticaria0
Pharmacy
Starting dose
60 mg PO BID or 180 mg PO once daily
Preparations
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC
US FDA Max
180 mg/d (adults)
Pharmacology
Routes
Oral
Onset
1-2 hours
Duration
12-24 hours
Half-life
~14 hours[1]
Bioavailability
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)[1]
Pregnancy
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.[citation needed]
Legal status
OTC in US
Purported mechanism
Fexofenadine is the active carboxylated metabolite of terfenadine (the latter withdrawn for QT-prolonging cardiotoxicity); it selectively antagonizes peripheral H1 receptors with minimal blood-brain barrier penetration and no significant CYP-mediated metabolism, giving it among the lowest-sedation and lowest-interaction profiles in the second-generation class.0 Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction).
References
- ↑ 1.0 1.1 FDA Prescribing Information, Allegra (fexofenadine HCl), Sanofi-Aventis (now OTC), current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020786s022,020872s019,021963s010lbl.pdf